Fig. 1: Progression-free survival. | Leukemia

Fig. 1: Progression-free survival.

From: Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

Fig. 1: Progression-free survival.

Patients with eGFR <60 mL/min/1.73 m² (a), <45 mL/min/1.73 m² (b), and ≥60 mL/min/1.73 m² (c) in the Isa-Pd and Pd arms. CI confidence interval, eGFR estimated glomerular filtration rate, HR hazard ratio, Isa-Pd isatuximab, pomalidomide, and dexamethasone, Pd pomalidomide and dexamethasone, PFS progression-free survival.

Back to article page